Advertisement

Topics

Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177

09:25 EDT 9 Jul 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Strategic Partnership supports Commercialization beyond ongoing Phase 3 VISION Trial of 177Lu-PSMA-617 Endocyte, Inc. (Nasdaq:ECYT), and ITM Isotopen Technologien München AG (ITM), a group of specialized radiopharmaceutical...

Other Sources for this Article

Endocyte Investor Contact:
Michael Schaffzin
Stern Investor Relations, Inc.
Phone: (212) 362-1200
Email: michael@sternir.com
or
ITM Media Contact:
Nicola Scharrer
Head of Marketing
Phone: +49 89 3298986-16
Email: Nicola.Scharrer@itm.ag

NEXT ARTICLE

More From BioPortfolio on "Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...